Table 2.
Parameters for pharmacodynamic model.
| Parameters | Estimates (%RSE) | SIR Medians (95% CIs) | Units | Sources | Definitions |
|---|---|---|---|---|---|
| Model Associated Parameters | |||||
| Kg0CTR | 0.00339 (6%) | 0.00339 (0.00325, 0.00352) | /h | Estimated | First order tumor growth rate constant for animals receiving no treatments |
| Kg0PTX | 0.00372 (9%) | 0.00367 (0.00338, 0.00397) | /h | Estimated | First order tumor growth rate constant for animals receiving PTX solution |
| Kg0PTXNP | 0.00417(5%) | 0.00418 (0.00394, 0.00445) | /h | Estimated | First order tumor growth rate constant for animals receiving PTX-PLGA NPs |
| Kg0MSC | 0.00588 (11%) | 0.00585 (0.00528, 0.00639) | /h | Estimated | First order tumor growth rate constant for animals receiving nano-MSCs |
| TVBLCTR | 0.360 (16%) | 0.365 (0.251, 0.488) | 106 photon/s | Estimated | Baseline tumor bioluminescence for animals receiving no treatments |
| TVBLPTX | 0.376 (43%) | 0.387 (0.208, 0.593) | 106 photon/s | Estimated | Baseline tumor bioluminescence for animals receiving PTX solution |
| TVBLPTXNP | 0.539 (18%) | 0.549 (0.365, 0.730) | 106 photon/s | Estimated | Baseline tumor bioluminescence for animals receiving PTX-PLGA NPs |
| TVBLMSC | 0.227 (14%) | 0.232 (0.173, 0.287) | 106 photon/s | Estimated | Baseline tumor bioluminescence for animals receiving nano-MSCs |
| KmaxPTX | 0.00343 (26%) | 0.00332 (0.00261, 0.00398) | /h | Estimated | Maximal tumor killing rate induced by PTX free drug |
| KmaxNP | 0.000427 (372%) | 0.000755 (0.000035, 0.002192) | /h | Estimated | Maximal tumor killing rate induced by PTX in the form of PLGA NPs |
| KMSC | 4.35 × 10−6 (30%) | 4.31 × 10−6 (2.79 × 10−6, 5.75 × 10−6) | /(h*(ng/mL)) | Estimated | Linear tumor killing rate constant induced by PTX in the form of nano-MSCs |
| IC50PTX | 1.5 | ng/mL | Literature [16] | Concentration of PTX free drug can introduce 50% KmaxPTX | |
| IC50NP | 5.7 | ng/mL | Literature [16] | Concentration of PTX in the form of PLGA NPs can introduce 50% KmaxNP | |
| Between Subject Variability (BSV, proportional, CV%) | |||||
| ηTVBL | 96.4% (9%) | 99.1% (77.3%, 123.6%) | Shrinkage (0%) | Estimated | BSV on baseline tumor bioluminescence |
| Residual Unexplained Variability (RUV, CV%) | |||||
| εPTX_plasma | 49.3% (5%) | 49.5% (45.1%, 53.7%) | Estimated | RUV for tumor bioluminescence profiles in animals receiving no treatments | |
| εPTX_tumor | 66.8% (7%) | 67.4% (59.1%, 76.6%) | Estimated | RUV for tumor bioluminescence profiles in animals receiving PTX solution | |
| εNP_plasma | 62.4% (8%) | 63.0% (54.9%, 71.2%) | Estimated | RUV for tumor bioluminescence profiles in animals receiving PTX–PLGA- NPs | |
| εNP_tumor | 62.2% (10%) | 63.0% (54.8%, 72.2%) | Estimated | RUV for tumor bioluminescence profiles in animals receiving nano-MSCs | |
Note: * indicate multiplication.